The critical role of DNA repair in ovarian cancer (OvCa) is underscored by the clinical success of poly(ADP-ribose) polymerase (PARP) inhibitors, particularly in patients with BRCA-mutated tumours. The gene discussed is PARP1; the disease is ovarian cancer.